Karen Liu, Ph.D., is a founding partner of 3E Bioventures Capital, a fund that focuses on venture investments in healthcare related sectors, such as drug, device, diagnostics, increasingly, interdisciplinary innovations at the frontier of BT (Biotech) and IT (information technology). While 3E primarily invests in China, it is also actively exploring cross-border investment opportunities.
Dr. Liu has been active in China healthcare venture investment since 2006. Her past investments include device and diagnostic companies, drug related companies, and mobile health companies. Prior to 3E Bioventures, Dr. Liu held various positions in healthcare investments as a partner at Kaiwu Capital and Managing Director at CRCI Capital.
In 2006, Dr. Liu co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angle investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company founded by Internet veteran Hongyi Zhou. She helped build up the small internet company and achieved profitability and eventually sold it to Yahoo in early 2004. Dr. Liu also worked as a consultant at McKinsey & Company from 1998-2000.
Dr. Liu received her Ph.D. degree in immunology from Harvard University and Master of Medical Sciences degree from Harvard Medical School. She also received her Bachelor of Sciences degree from Cornell University and her EMBA degree from the Chungkong Graduate School of Business (CKGSB) in China.